You are here

Studies Suggest Statins Could Lessen Effectiveness of Flu Vaccine

Antibody production is lower and respiratory infections higher in patients who received both

Around this time of year, flu shots are very popular and widely recommended by doctors — especially for older people. But interesting evidence warns that statins, the most widely used cholesterol-lowering drugs, may reduce the response to the flu vaccine.

Time notes that every flu season, doctors repeat the same advice: Get your shot. And for some groups, including the elderly, that recommendation is especially important — each year, nearly 3,000 people more than 65 years old die from the flu. But in two papers published in the Journal of Infectious Diseases, researchers report that people taking statins for lengthy periods of time have a dampened response to the flu vaccine and that they are more likely to see the doctor during flu season for influenza symptoms.

Dr. Steven Black, professor of pediatrics at the Center for Global Health at the Cincinnati Children’s Hospital, and his colleagues reviewed data involving more than 5,000 people over age 65 who received one of two different forms of a flu vaccine during the 2009–2010 and 2010–2011 flu seasons. Because the study also asked the participants about their medications, the researchers could compare people who took statins to those who did not. It turns out that statin users produced anywhere from 30% to 60% fewer antibodies to the influenza virus 22 days after getting immunized than those who didn’t take statins.

In the second study, Emory University’s Saad Omer and colleagues studied rates of respiratory infection, an indication of influenza, across nine flu seasons among members of a managed care group in Georgia. When they added in information on the patients’ statin use, they found that the effectiveness of the vaccine in preventing those infections was 12.6% among statin users, compared with 26.2% among those not taking statins.

The results set the stage for a rethinking about what older patients taking statins should do about their yearly flu shots. Black says he opted for the higher-dose flu vaccine this year because he takes a statin. The higher-dose shot is boosted with more influenza antigen, which is supposed to do a better job at triggering the immune system into action and create more antibodies against the flu virus. There are also vaccines bolstered with adjuvant that also helps to awaken the immune system, but these are not approved yet by the FDA, although they are available in Canada and Europe.

What people should not do, experts say, is stop taking their statins or skip the flu shot.

“We know statins improve survival in people with [high cholesterol] and heart disease, so they should be taken,” says Dr. Robert Atmar, professor of medicine and chief of infectious diseases at Baylor College of Medicine, who wrote an editorial accompanying the studies. “We know that flu vaccines decrease the risk of influenza and complications from influenza infection and should be taken.”

He notes that while statins seem to decrease responses to the flu vaccine, they didn’t suppress them altogether, so even if you are taking statins, you will still get some protection from the flu vaccine.

What the latest results suggest is the need for further studies to answer questions such as whether people should temporarily stop taking statins around the time they get vaccinated against the flu, or whether the higher-dose vaccines, like the one Black took, can compensate for the muted responses to the vaccine.

Source: Time, October 30, 2015.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential